港股異動 | 長江生命科技(0775.HK)漲6.38% 李嘉誠投資新冠檢測技術將面世
格隆匯9月4日丨長江生命科技(0775.HK)連續兩日逆市受捧,現漲6.38%,報1港元,成交6536萬港元,總市值96億港元。李嘉誠創辦的長江生命科技早前宣佈,分銷新加坡血清學試劑盒,10分鐘就能驗出新冠病毒抗體。而李嘉誠私人的維港投資亦有斥資支持紐約科企Homodeus,利用其恆温技術“LAMP”,每次花費數十港元,就能在家中快捷檢測到體內有否潛藏病毒的遺傳物質,港人或成為Homodeus首批用户。相關驗毒技術預料下月面世。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.